Impaired mitochondrial β-oxidation in patients with chronic hepatitis C: relation with viral load and insulin resistance

BMC Gastroenterology

Table 1 Patient characteristics

		Patients	Reference value
Age (yr) ^b		54.2 ± 10.6
Male/Female (ratio)		14/16 (0.47)
BMI (kg/m²) ^b		23.7 ± 2.7	18.5 - 25
ALT (IU/L) ^a		47.5 (17–167)	8 - 42
γGTP (IU/L) ^a		41 (13–152)	10 - 47
ChE (IU/L) ^b		312.9 ± 88.2	185 - 431
Fasting plasma glucose (mg/dL) ^b		95.5 ± 9.7	70 - 109
Insulin (μIU/mL) ^a		8.7 (4.5 - 20.4)	1.84 - 12.2
HOMA-IR ^a		2.0 (1.2 - 5.1)
HOMA-IR > 2.5 (%)		9 (30)
Triglyceride (mg/dL) ^b		91.4 ± 31.1	30 - 149
Total cholesterol (mg/dL) ^b		175.2 ± 25.4	129 - 219
Acylcarnitine (μmol/L) ^a		9.25 (5.7 - 21.1)	6 - 23
HCV RNA (LogIU/mL) ^b		6.1 ± 0.9
HCV core antigen (fmol/L) ^a		6505 (<20–23200)
HCV Genotype	1b / 2a / 2b	20 / 6 / 4
Inflammation	A0 / A1 / A2 / A3	0 / 15 / 10 / 0
Fibrosis	F0 / F1 / F2 / F3 / F4	0 / 15 / 7 / 3 / 0
Steatosis	G0 / G1 / G2 / G3	6 /18 / 1 / 0

BMI, body mass index; ALT, alanine aminotransferase; γGTP, gamma-glutamyltranspeptidase; ChE, cholinesterase; HOMA-IR, homeostasis model assessment of insulin resistance.
Data are ^amedians (min-max), ^bthe means ± standard deviation.